Why Alnylam Pharmaceuticals (ALNY) Stock Is Up Today

Alnylam Pharmaceuticals (ALNY) is up 5.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be a continued rebound after investors reassessed Alnylam’s late-July selloff. While the company trimmed part of its 2026 sales outlook, the underlying business still showed very strong revenue growth, and bullish Wall Street sentiment seems to be helping shares recover. No single new company-specific announcement appears to fully explain today’s move, so part of the gain could be momentum tied to that reassessment.

Details:

Alnylam’s second-quarter 2026 results showed global net product revenue of $1.17 billion, including $1.03 billion from its transthyretin franchise, marking strong year-over-year growth.

The company lowered full-year 2026 TTR revenue guidance to $4.2 billion to $4.5 billion, citing a normalization in second-line AMVUTTRA demand after an earlier burst of pent-up demand.

Even with that guidance reset, Alnylam kept highlighting continued ATTR-CM launch progress, ongoing pipeline advancement, and more than $3 billion in cash, cash equivalents, and marketable securities.

Analyst sentiment earlier in August turned constructive after the post-earnings pullback, which likely encouraged bargain-hunting as investors weighed the company’s long-term franchise and pipeline value against the recent decline.

Sources:

Alnylam, SEC, Yahoo Finance

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ALNY Insider Trading Activity

$ALNY insiders have traded $ALNY stock on the open market 130 times in the past 6 months. Of those trades, 0 have been purchases and 130 have been sales.

Here’s a breakdown of recent trading of $ALNY stock by insiders over the last 6 months:

PUSHKAL GARG (EVP Chief R&D) has made 0 purchases and 31 sales selling 12,832 shares for an estimated $4,188,026.
YVONNE GREENSTREET (Chief Executive Officer) has made 0 purchases and 18 sales selling 9,732 shares for an estimated $3,175,279.
JEFFREY V. POULTON (EVP, Chief Financial Officer) has made 0 purchases and 18 sales selling 4,674 shares for an estimated $1,520,151.
KEVIN JOSEPH FITZGERALD (CSO & EVP, Head of Research) has made 0 purchases and 26 sales selling 4,541 shares for an estimated $1,469,458.
MELISSA MCLAUGHLIN (Chief Human Resources Officer) has made 0 purchases and 14 sales selling 3,910 shares for an estimated $1,274,342.
TOLGA TANGULER (EVP, Chief Commercial Officer) has made 0 purchases and 18 sales selling 3,907 shares for an estimated $1,269,567.
DAVID E I PYOTT has made 0 purchases and 5 sales selling 3,830 shares for an estimated $1,145,852.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$ALNY Hedge Fund Activity

We have seen 417 institutional investors add shares of $ALNY stock to their portfolio, and 477 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 4,490,826 shares (+390.0%) to their portfolio in Q2 2026, for an estimated $1,351,873,350
JPMORGAN CHASE & CO added 2,675,517 shares (+inf%) to their portfolio in Q2 2026, for an estimated $805,410,882
INVESCO LTD. added 2,462,592 shares (+190.6%) to their portfolio in Q2 2026, for an estimated $741,314,069
MARSHALL WACE, LLP removed 839,519 shares (-76.4%) from their portfolio in Q2 2026, for an estimated $252,720,404
DEEP TRACK CAPITAL, LP added 825,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $248,349,749
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 755,377 shares (+inf%) to their portfolio in Q2 2026, for an estimated $227,391,138
D. E. SHAW & CO., INC. added 659,616 shares (+148.4%) to their portfolio in Q2 2026, for an estimated $198,564,204

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$ALNY Analyst Ratings

Wall Street analysts have issued reports on $ALNY in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 06/29/2026

To track analyst ratings and price targets for $ALNY, check out Quiver Quantitative's $ALNY forecast page.

$ALNY Price Targets

Multiple analysts have issued price targets for $ALNY recently. We have seen 7 analysts offer price targets for $ALNY in the last 6 months, with a median target of $425.0.

Here are some recent targets:

Patrick R. Trucchio from HC Wainwright & Co. set a target price of $470.0 on 06/29/2026
Eric Joseph from Citigroup set a target price of $380.0 on 05/19/2026
Derek Archila from Wells Fargo set a target price of $377.0 on 05/01/2026
Luca Issi from RBC Capital set a target price of $445.0 on 05/01/2026
Danielle Brill from Truist Securities set a target price of $505.0 on 04/13/2026
Keay Nakae from Chardan Capital set a target price of $425.0 on 03/25/2026
Faisal Khurshid from Jefferies set a target price of $330.0 on 03/16/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.